Growing evidence supports the potential clinical use of blood GFAP levels in numerous neuroinflammatory and neurodegenerative diseases including head trauma, multiple sclerosis, intracerebral hemorrhage, and ischemic stroke (Vos et al., 2004; Foerch et al., 2012; Kraljević et al., 2024; Ayrignac et al., 2020). This evidence concerns the gene GFAP and ischemic stroke.